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Background: The novel antiepileptic drug (AED) levetiracetam (LEV, Keppra®) is indicated as adjunctive therapy for partial
epilepsy. The primary aim of this study was to measure the safety and tolerability of LEV individualised dosing in a heterogeneous
refractory epilepsy population.
Methods: LEV was evaluated in a 10- to 16-week open-label, multicentre study in adult patients with epilepsy refractory
to previous treatment with at least two AEDs. Individualised LEV doses up to 3000 mg day−1 were determined in an ini-
tial up-titration phase, and optimal doses were administered as adjunctive treatment during an 8- to 10-week evaluation
period. Concomitant AEDs and their doses could not be changed during the study. Safety and tolerability were monitored
by expression of adverse events as well as by retention rate. The effect of LEV on concomitant AED concentration was
also studied. Efficacy was assessed using global clinical evaluation (GCE) scores, seizure frequency, and ≥50% responder
rate.
Results: LEV therapy was initiated in 219 patients; 183 had localisation-related epilepsy and 37 had generalised epilepsy. In
one patient, epileptic syndrome was defined as both localisation-related and generalised. About 81.7% (179/219) continued and
completed treatment throughout the study, and 79% (172/219) chose to continue LEV in a follow-up study. The most common
adverse events were asthenia, dizziness, and somnolence. Most adverse events occurred during up-titration. LEV treatment did
not alter the concentration of concomitant AEDs. LEV improved GCE scores in 79.5% (152/191) of patients. LEV reduced
the median total seizure frequency of all patients from a median of 2.25 seizures per week at baseline (n = 219) to 1.10
seizures per week during the evaluation period (n = 191 patients with at least one seizure count during evaluation). The ≥50%
responder rate was 48.2% for all seizure types, 49.4% for partial-onset, and 51.4% for generalised-onset seizures. Throughout
the evaluation period (i.e. from the start of the evaluation period until completion or early discontinuation), 26/191 (13.6%) had
a 100% reduction in total seizure frequency, while in a follow-up study, 10.5% (18/172) were seizure-free for at least 6 months
and 6.4% (11/172) were seizure-free for at least 1 year.
Conclusion: LEV was well tolerated, as evidenced by limited adverse event reporting and the high retention rate, and appeared
effective in both generalised and partial epilepsy.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Levetiracetam ((S)-alpha-ethyl-2-oxo-pyrrolidine ac-
etamide; Keppra®; Keppra is a registered trademark
of UCB S.A.) is an antiepileptic drug (AED) approved
for marketing in 28 countries, including the US,
European Union, and Australia, as an adjunct treat-
ment for partial epilepsy. Levetiracetam is rapidly and
almost completely absorbed following oral admin-
istration and exhibits near linear pharmacokinetics1.
Interactions with other drugs are unlikely, since leve-
tiracetam has minimal protein binding and is neither
metabolised by nor interacts with specific hepatic en-
zymes. Minimal metabolism to an inactive metabolite
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occurs, and both compounds are excreted in urine1, 2.
Levetiracetam has a half-life of 6–8 hours, allowing
for twice-daily dosing1, 3.
The precise mechanism(s) by which levetiracetam
exerts its antiepileptic effect is unknown; however,
the mechanism of action appears to differ from that
of other AEDs4. Levetiracetam does not modulate
Na+ and T-type Ca2+ channels5 and does not in-
duce any conventional modulation of the GABAergic
system6 or ionotropic excitatory glutamate receptors7.
Levetiracetam has been shown to potently antago-
nise negative modulators of both GABA and glycine
receptors6. Other potential mechanisms underlying
its antiepileptic action involve inhibition of high
voltage-activated calcium currents8 and a moderate
suppression of the delayed rectifier K+ current9.
Levetiracetam’s antiepileptic effect may relate to an
interaction with a brain-specific binding site10.
Levetiracetam’s potential as a broad-spectrum AED
with a wide margin of safety was apparent from an-
imal models of partial and generalised epilepsy11–14.
Results from phase II clinical trials evaluating leve-
tiracetam as add-on therapy in patients with refrac-
tory partial and/or secondarily generalised seizures
demonstrated that doses up to 4000 mg day−1 are ef-
fective and well tolerated15, 16. The antiepileptic effi-
cacy and tolerability of levetiracetam were confirmed
in phase III studies, in which patients with refractory
partial seizures with or without secondary generalisa-
tion received 1000, 2000, or 3000 mg day−1 as adjunc-
tive therapy or were converted to monotherapy17–19.
Levetiracetam significantly reduced seizure frequency
regardless of seizure subtype.
The objective of this study was to add patient expo-
sure, regardless of seizure type, to the safety database.
In addition, this study was designed to obtain a
standardised descriptive evaluation of the safety and
efficacy of levetiracetam at individualised doses up to
3000 mg day−1 in patients with refractory epilepsy.
METHODS
Study design
In this multicentre, noncomparative, open-label phase
III study, individualised doses of levetiracetam were
evaluated in patients who were refractory to previous
treatment with at least two AEDs. The study consisted
of a 4-week retrospective baseline, a 2- to 6-week
up-titration, and an 8- to 10-week evaluation period.
This study followed Good Clinical Practice, the Dec-
laration of Helsinki, and was supervised by an Inde-
pendent Ethics Committee.
All patients initially received 1000 mg day−1 of
levetiracetam (500 mg b.i.d. orally), which was man-
ufactured and packaged by UCB S.A., Brussels. The
dose was up-titrated at clinic visits every 2 weeks
in steps of 1000 mg day−1 up to a maximum of
3000 mg day−1, until an optimal individualised eval-
uation dose of 1000, 2000, or 3000 mg day−1 was
achieved. Optimal doses were determined based on
improvement in seizure expression and absence of
substantial adverse events. If no remarkable improve-
ment in seizure control occurred and there were no
significant drug-related adverse events at lower doses,
3000 mg day−1 of levetiracetam was considered the
optimal dose. The duration of the up-titration pe-
riod was 2–6 weeks, depending on how quickly an
effective dose was reached. After every visit during
the titration period, the investigator could decide to
titrate upwards from 1 to 2 g or from 2 to 3 g, if
seizures were still occurring and no adverse effects
were seen. The investigator could down-titrate from
3 to 2 g or from 2 to 1 g if there were unacceptable
adverse effects. Patients could enter the evaluation
period without further titration if a marked improve-
ment had been experienced and no significant adverse
effects were seen, or if the patient did not wish to
make additional changes.
During the 8- to 10-week evaluation period, patients
received their individualised optimal levetiracetam
dose as an adjunct to their stable regimen of concomi-
tant AED therapy. Patients who wanted to terminate
treatment entered a variable period of gradual with-
drawal in which the levetiracetam dose was reduced
by no more than 1000 mg every 3–7 days. A final
clinical evaluation was undertaken 2 weeks following
the termination of treatment. After completion of the
evaluation period, patients were given the option of
entering a continuation study.
Patient selection
Patients aged 16–70 years were eligible for this study
if they had uncontrolled seizures that were classifi-
able according to the International Classification of
Epileptic Seizures and treated with at least one and
at most three concomitant AEDs at a stable dose
regimen for at least 4 weeks prior to study initiation.
Patients with either partial-onset seizures or gener-
alised seizures were included. Female patients of
childbearing potential were accepted only if adequate
birth control measures were followed. Patients were
excluded from this study if they were taking tiagabine
or felbamate as standard AED treatment, barbiturates
(except phenobarbital), benzodiazepines, or any med-
ication that could affect CNS function (with the ex-
ception of approved AEDs). Tiagabine was excluded
because of a lack of ability to assay plasma levels.
Felbamate was excluded because of the potential risk
of aplastic anaemia and hepatic failure20.
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Patients were also excluded if they had a history
of psychiatric disorder, drug or alcohol abuse, se-
vere or multiple drug allergies, impaired hepatic or
renal function, clinically significant disease, or cere-
brovascular accident or cerebral tumours. Pregnant
or lactating patients were excluded, as were patients
participating in another clinical trial within 8 weeks
of the start of the study or any time during the study.
Patients could discontinue the study if they failed to
comply with the protocol or drug treatment regimens,
if they wished to terminate treatment, if the study
treatment failed to prove beneficial, or if adverse
events were sufficiently severe. All patients gave
written informed consent prior to any study-specific
procedures.
Data collection
Safety
Clinical assessments included medical histories as
well as physical and neurological examinations at
each visit. The incidence, nature, and severity of ad-
verse events and their relationship to levetiracetam
were recorded. Adverse events were classified ac-
cording to Coding Symbols for Thesaurus of Adverse
Reaction Terms (COSTART). Laboratory tests, in-
cluding blood (20 ml) and urine samples (midstream),
were conducted at each visit, and 12-lead ECGs were
conducted at the beginning and the end of study
participation. Samples were analysed for standard
haematology, blood and serum chemistry, and urinal-
ysis measures. Trough plasma levels of levetiracetam,
concomitant AEDs, and metabolites were analysed at
every visit from blood samples taken approximately
12 hours post-dose.
Efficacy
Efficacy was measured by the global clinical evalua-
tion (GCE) scale as well as seizure counts. Patients
were rated as clearly improved (4), improved (3), sta-
ble (2), worsened (1), or clearly worsened (0) com-
pared to the pretrial period and selection visit, and
results were reported as a percentage of patients.
The total number of seizures per patient and the
number per seizure type were also recorded. Seizure
counts were determined from patient self-reporting on
daily report cards containing the date and time of on-
set, number of seizures, and description of seizures.
Responder rates were calculated as the percentage of
patients who showed a reduction of 50% or more in
seizure frequency per week compared to the 4-week
retrospective baseline. Responder rates were calcu-
lated for total seizures, for partial-onset and gener-
alised seizures, and for patient subgroups based on
concomitant AED.
Statistical analysis
Safety analysis was performed on a total of 219 pa-
tients in the intent-to-treat population who received at
least one dose of levetiracetam. Efficacy analysis was
performed on patients who completed the titration pe-
riod and had at least one assessment in the evaluation
period. Safety and efficacy data were assessed using
descriptive statistics, including mean and standard de-
viation, and median with minimum and maximum.
The number and percentage of patients who reported
adverse events was tabulated by study period, body
system, COSTART preferred term, severity, and rela-
tionship to treatment.
RESULTS
Patient characteristics and disposition
This study was initiated in January 1998 and com-
pleted in October 1998. A total of 232 patients from 13
centres in Europe and the United States were screened;
219 received at least one dose of levetiracetam. A total
of 191 patients completed the titration and entered the
evaluation period. The disposition of patients through-
out the study is illustrated in Fig. 1.
The study population consisted primarily (95%) of
Caucasians and included approximately equal num-
bers of men (52%) and women (48%). The mean age
of patients in the study was 36 ± 13 years (Table 1).
The aetiology of epilepsy was unknown for 43.8%
(96/219) of the patients, whereas it was determined
to be genetic in 11.9% (26/219), caused by cranial
trauma in 11.4% (25/219), and due to cerebral in-
fection in 9.1% (20/219). The mean age at epilepsy
onset was 12 ± 11 years, and the mean duration of
epilepsy was 24 ± 13 years. About 183 patients had
localisation-related epilepsy and 37 patients had gen-
eralised epilepsy. In one patient, epileptic syndrome
was defined as both localisation-related and gener-
alised.
Of the patients with generalised epilepsy, 32%
(12/37) were diagnosed by the investigator as having
juvenile myoclonic epilepsy. Four others (11%) had a
combination of myoclonic and absence seizures with
or without generalised tonic-clonic seizures. This
combination of seizure types suggests juvenile my-
oclonic epilepsy, even though this syndrome diagnosis
was not specifically stated. One patient was diagnosed
with juvenile absence epilepsy. Three patients (8.3%)
had isolated generalised tonic-clonic seizures. Four
patients (11%) were diagnosed with Lennox–Gastaut
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Fig. 1: The disposition of patients.
Syndrome, and four others (11%) were diagnosed
with symptomatic generalised epilepsy, not further
specified. In the eight remaining patients with gener-
alised epilepsy, further epilepsy classification was not
specified. A history of status epilepticus was reported
in 23.7% of all patients.
At the last visit, 121 (55.3%) patients were taking
>2000–3000 mg day−1 of levetiracetam, 56 (25.6%)
were taking >1000–2000 mg day−1, 39 (17.8%) were
taking ≤1000 mg day−1, and three (1.4%) were tak-
ing >3000–4000 mg day−1. The most common con-
comitant AEDs (given to >10% of patients) were
carbamazepine (47.0%), lamotrigine (41.1%), topira-
mate (25.1%), valproate (27.9%), phenytoin (22.8%),
and gabapentin (19.6%).
Tolerability and safety
A total of 196 of 219 patients (89.5%) reported
treatment-emergent adverse events. The frequency of
adverse events did not appear to be dose-dependent
(Table 2). The patient population receiving the low-
est dose of levetiracetam (1000 mg) (at the end of
the study) exhibited the highest percentage of those
adverse events most frequently reported (asthenia,
dizziness, somnolence, and nervousness). There was
no apparent correlation between the distribution of ad-
verse events and specific concomitant AEDs. Adverse
events were most prevalent early in the study: 81.8%
of patients reported adverse events during up-titration,
66.3% during the evaluation phase, and 22.6% during
down-titration. The most common adverse events in
all three dosage groups were asthenia, dizziness, and
somnolence (Table 2). A total of 31 of 219 patients
(14.2%) had adverse events that led to the discon-
tinuation of levetiracetam treatment, most commonly
(27 patients) during up-titration. Convulsion was the
most common reason for withdrawal (13/31; 42%).
Treatment-emergent behavioural adverse events
included nervousness (21/219; 9.6%), depression
(16/219; 7.3%), hostility (9/219; 4.1%), personality
disorder (8/219; 3.7%), emotional liability (6/219;
2.7%), anxiety (5/219; 2.3%), psychosis (2/219;
0.9%), agitation (2/219; 0.9%), euphoria (2/219;
0.9%), suicide attempt (1/219; 0.5%), and hallucina-
tions (1/219; 0.5%). (Some patients reported more
than one.) Most of these events were mild or mod-
erate in severity. They were severe in seven patients
(three patients with symptoms of hostility and one
patient each with symptoms of depression, nervous-
ness, personality disorder, and psychosis). The severe
symptoms of psychosis, depression, and nervousness
were considered to be possibly related to levetirac-
etam treatment, and one expression of hostility was
considered probably related to treatment. Two severe
events of hostility and one severe event of personal-
ity disorder were considered to be unlikely related
to levetiracetam. At the time of the suicide attempt,
the patient was taking 2000 mg day−1. All other
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Table 1: Baseline demographic and clinical characteristics
(intent-to-treat population).
Characteristic Levetiracetam (n = 219)
Age (years)
N 219
Mean ± SD 36 ± 13
Body mass index (kg m−2)
N 210
Mean ± SD 26.7 ± 5.9
Height (cm)
N 211
Mean ± SD 169.6 ± 9.7
Weight (kg)
N 216
Mean ± SD 76.8 ± 19.5
Gender, N (%)
Male 114 (52.1)
Female 105 (47.9)
Race, N (%)
Caucasian 208 (95.0)
Black 9 (4.1)
Asian 2 (0.9)
Onset of epilepsy
N 218
Mean age (years) ± SD 12 ± 11
Duration of epilepsy
N 218
Mean (years) ± SD 24 ± 13
Concomitant AED at selection visit, N (%)
1 46 (21)
2 116 (53)
3 47 (21.5)
>3 10 (4.6)a
a Three of these ten patients were considered as protocol
violators. Seven took a fourth antiepileptic drug (AED)
sporadically and were not considered to be protocol violators.
behavioural adverse events occurred with similar fre-
quency across all doses (≤1500, >1500 to ≤2500,
>2500 to ≤3500 mg day−1). Seven patients discon-
tinued levetiracetam because of behavioural adverse
events. Reasons for withdrawal included psychosis
Table 2: The most frequent adverse events occurring in ≥10% of patients (percentage of patients within each dosage group)
presented by levetiracetam dose at the end of the study.
Adverse event ≤1000 mg day−1 (n = 39) >1000 to ≤2000 mg day−1 (n = 56) >2000 to ≤3000 mg day−1 (n = 121)
Asthenia 35.9 39.3 33.1
Dizziness 33.3 19.6 22.3
Somnolence 28.2 30.4 14.9
Nausea 17.9 3.6 9.1
Nervousness 15.4 8.9 8.3
Thinking abnormal 12.8 1.8 1.7
Anorexia 10.3 3.6 6.6
Headache 7.7 19.6 15.7
Infection 2.6 10.7 13.2
Diplopia 2.6 10.7 6.6
Convulsion 7.7 14.3 10.7
Accidental injury 7.7 5.4 14.0
(two patients), attempted suicide (one patient), and
anxiety, depression, hostility, and personality disor-
der (one patient each). In most cases no action was
required; patients fully recovered.
There were no clinically meaningful changes in
physical and neurological examination or in ECG
throughout the study. Vital signs did not change
significantly over the study period.
Laboratory measures
Plasma levels of concomitant AEDs were not changed
by the addition of levetiracetam. Mean trough plasma
levels (µg ml−1 ± SD) prior to levetiracetam treat-
ment, during up-titration, and during evaluation are
shown in Table 3.
There was little or no change from baseline in the
mean laboratory values for all parameters during the
study; values were generally within the normal range.
The white blood cell count was decreased in nine pa-
tients and increased in one patient. Urinalysis values
showed elevated white or red blood cell counts in
nine and fourteen patients, respectively, and elevated
protein concentrations in two patients. However,
none of these values were considered to be clinically
significant and none warranted the termination of
levetiracetam.
Efficacy
Global clinical evaluation (GCE)
Of the 191 patients who had a GCE score at baseline
and during the evaluation period, 152 (79.5%) showed
improvement following treatment with levetiracetam
(GCE rating of 3 or 4). Nine (4.7%) patients wors-
ened (GCE rating of 1). When patients were evaluated
by seizure type, 78.9% (127/161) with partial-onset
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Table 3: Plasma levels of concomitant antiepileptic drugs (AEDs).
AED Before levetiracetam During up-titration During evaluation
Carbamazepine 8.6 ± 2.7 8.7 ± 2.2 8.4 ± 2. 3
Carbamazepine-10,11-epoxide 2.2 ± 1.1 2.4 ± 1.0 −2.5 ± 1.1
Lamotrigine 6.4 ± 3.5 6.4 ± 3.8 6.3 ± 4.1
Valproate 78.1 ± 30.3 73.4 ± 29.9 66.4 ± 30.8
Topiramate 10.0 ± 7.7 9.2 ± 6.7 9.4 ± 6.3
Phenytoin 17.9 ± 8.4 17.6 ± 7.5 17.9 ± 7.5
Gabapentin 9.2 ± 4.9 7.8 ± 3.7 8.4 ± 3.5
seizures and 80.6% (25/31) with generalised-onset
seizures showed improvement in the GCE at the end
of the evaluation period compared to baseline. Fig. 2
shows the GCE scores according to the last leve-
tiracetam dose. The median GCE score at all visits
during the up-titration and the evaluation period for
all patients was 3 (improved).
Median seizure frequency
Seizure frequency was evaluated on the population
with at least one seizure of the type analysed dur-
ing baseline or with at least one assessment during
evaluation. Levetiracetam reduced the median total
seizure frequency of all patients from a median of
2.25 (range = 0–125) seizures per week at baseline
(n = 219) to 1.10 (range = 1–105) seizures per
week during the evaluation period (n = 191 patients
with at least one seizure count during evaluation).
Seizure frequency was also evaluated separately
by seizure type for patients with partial-onset or
generalised-onset seizures on the subsets of patients
with at least one seizure during baseline or the evalu-
ation period. In patients presenting with partial-onset
Fig. 2: GCE score by levetiracetam dose at the end of the study.
seizures, the median seizure frequency was reduced
from 2.00 (range = 0–76, n = 186) to 1.05 (range =
0–62, n = 158) seizures per week. In patients with
generalised-onset seizures at baseline and/or during
the evaluation period, the median seizure frequency
was reduced from 1.50 (range = 0–125, n = 65)
seizures per week to 1.30 (range = 0–105, n = 37)
seizures per week. (Out of the 65 patients included
in this subset, 21 discontinued before entering the
evaluation period and seven had missing seizure
frequency per week assessments for the evaluation
period. Therefore, these could not be included in the
seizure frequency per week calculation.)
Responder rate
The responder rate was defined in the population
with at least one seizure count of the analysed type
during baseline or evaluation and at least one assess-
ment during the evaluation period. The responder
rate, or percentage of patients with a ≥50% reduc-
tion in seizure frequency, was 48.2% (92/191) for
all seizure types, 49.4% (78/158) for patients with
partial-onset seizures, and 51.4% (19/37) for patients
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Table 4: Responder rate over the evaluation period.
Total (N = 219), Levetiracetam dose at end of study
% (n) ≤1000 mg day−1 >1000–≤2000 mg day−1 >2000–≤3000 mg day−1 >3000–≤4000 mg day−1
(N = 39), % (n) (N = 56), % (n) (N = 121), % (n) (N = 3), % (n)
All seizure types 48.2a (92/191) 52.0 (13/25) 51.1 (24/47) 45.7 (53/116) 66.7 (2/3)
Partial-onset 49.4b (78/158) 60.0 (12/20) 52.8 (19/36) 46.0 (46/100) 50.0 (1/2)
Generalized-onset 51.4b (19/37) 42.9 (3/7) 55.6 (5/9) 50.0 (10/20) 100.0 (1/1)
a All patients with at least one assessment during evaluation; b All patients with at least one seizure of the analysed type during baseline
or evaluation and at least one assessment during evaluation.
Table 5: Responder rate by concomitant antiepileptic drug (intent-to-treat population).
All seizure types, % (n) Partial-onset, % (n) Generalized-onset, % (n)
Carbamazepine 56.2 (50/89) 61.8 (47/76) 43.8 (7/16)
Lamotrigine 48.7 (38/78) 45.8 (27/59) 60.0 (12/20)
Valproate 50.0 (27/54) 45.7 (16/35) 59.1 (13/22)
Topiramate 47.1 (24/51) 49.0 (24/49) 0.0 (0/4)
Phenytoin 32.6 (14/43) 33.3 (13/39) 25.0 (1/4)
Gabapentin 44.4 (16/36) 45.7 (16/35) 100.0 (1/1)
with generalised seizures. Table 4 shows the respon-
der rate by final dosage. The number and percentage
of responders by seizure type and the most common
concomitant AED treatment are shown in Table 5.
The data further showed that 59 of 191 patients
(30.9%) with all seizure types had at least a 75% re-
duction in total seizure frequency, and that 26 (13.6%)
had a 100% reduction in total seizure frequency,
becoming seizure-free throughout the evaluation pe-
riod (i.e. from the start of the evaluation period until
completion or early discontinuation). Among patients
with partial-onset seizures, 31% (49/158) had at least
a 75% reduction in seizure frequency and 16.5%
(26/158) became seizure-free. Among those with
generalised-onset seizures, 40.5% (15/37) had at least
a 75% reduction in seizure frequency, and 8% (3/37)
became seizure-free.
Long-term follow-up
After completion of the evaluation period, patients
could enter a follow-up study. Long-term follow-up
was not analysed as a separate study, but patients were
entered in the database that consisted of all patients
ever exposed to levetiracetam during the development
program (n = 1422). The cut-off date for analysis
was June 1999, because follow-up was discontinued
upon registration of levetiracetam21. Of the 179 pa-
tients who completed evaluation in the initial study,
172 (96%) chose to continue adjunctive levetiracetam
treatment. The median duration of levetiracetam expo-
sure in patients entering the follow-up study was 391
days (range = 95–563). During follow-up, the dose
of levetiracetam was increased in 55.8% (96/172) of
patients. This included 15/21 patients whose last dose
in the initial study had been ≤1000 mg, 29/46 whose
last dose had been >1000 but ≤2000 mg, and 52/102
whose last dose had been >2000 but ≤3000 mg.
During follow-up, 21.5% (37/172) of patients had
a change in concomitant AED therapy. In 11.6%
(20/172), another AED was added to the treatment
regimen. Concomitant AED therapy was stopped in
11% (19/172) of patients. (In two patients, an AED
was both stopped and added.)
Among patients entering the follow-up study, 10.5%
(18/172) were seizure-free for at least a 6-month
period during their total exposure (initial study and
follow-up). In the same subset of the population, 6.4%
(11/172) of patients were seizure-free for at least a
1-year period during their total exposure (initial study
and follow-up). In patients receiving treatment for
longer than 1 year, 13.2% (18/136) were seizure-free
for a period lasting at least 6 months, and 8.1%
(11/136) were seizure-free for at least 1 year.
DISCUSSION
The primary goal of this study was to determine the
safety and tolerability of optimised doses of levetirac-
etam when given as an adjunct treatment. A sensitive
measure of short-term tolerability is continuation
rate. The retention rate for levetiracetam was high
(81.7%; 179/219) throughout the initial study. In addi-
tion, 96% (172/179) of patients completing the study
chose to continue levetiracetam in a follow-up study.
Long-term retention rates were similar to those previ-
ously described21. The most common adverse events
attributed to treatment, asthenia, somnolence, and
dizziness, were also experienced by patients in other
double-blind clinical studies of levetiracetam15, 17–19.
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The adverse events experienced by patients in Europe
and the USA were similar in nature and extent. The
frequency of adverse events was not correlated with
the final dose. Contrary to expected dose-response
effects, patients receiving the lowest dose of leve-
tiracetam at the end of the study exhibited the highest
percentage of those adverse events most frequently
reported (asthenia, dizziness, somnolence, and ner-
vousness). This tendency may reflect an increased
likelihood of patients to remain at or to go back to
a lower dosage if they are having difficulty tolerat-
ing levetiracetam. The majority of patients received
higher dosages and exhibited lower frequencies of
adverse events. The majority of adverse events oc-
curred early in treatment, during up-titration. These
findings suggest that adverse events are triggered by
the initial exposure to levetiracetam but abate over
time. Therefore, we would expect that after an initial
adjustment to levetiracetam treatment, adverse events
would not be common.
Behavioural adverse events were somewhat higher
than in double-blind clinical trials. However, be-
havioural adverse events were each reported in less
than 10% of the treated population, and many of
them were reported in less than 1%. The most com-
mon events included nervousness and depression.
The overall incidence of these events was relatively
low and did not require discontinuation of treatment
in most cases. It is encouraging that behavioural
events had a low incidence, did not usually require
the discontinuation of levetiracetam, and were not
dose-dependent.
There was little or no change in blood or urinalysis
laboratory values for all parameters tested. Changes
in white blood cell counts and red blood counts were
not clinically significant. There were no clinically
meaningful changes in physical and neurological
examination or in ECG during the study. Also, con-
sistent with levetiracetam’s pharmacokinetic profile,
levetiracetam treatment did not alter the mean trough
plasma levels of concomitant AEDs. Although this
study was not specifically designed to test efficacy,
levetiracetam markedly reduced seizure frequency
for both partial and generalised seizures. The respon-
der rates were approximately 50% for partial-onset
and generalised-onset seizure subgroups for most
doses tested, suggesting that similarly effective indi-
vidual dosages were achieved in all groups. A total
of 79.5% of patients experienced improvement in
their GCE score after levetiracetam treatment. Of the
191 patients who entered the evaluation period and
had evaluable efficacy measurements, 13.6% were
seizure-free from the start of the evaluation period
until completion or early discontinuation. The most
clinically relevant indicator of efficacy is the dura-
tion of seizure freedom. When pooling this study
with the long-term follow-up treatment of patients,
10.5% of patients were seizure-free for at least 6
months and 6.4% were seizure-free for at least 1
year. These results show that levetiracetam compares
very favourably with new potent AEDs in rendering
patients seizure-free with optimised doses, with few
discontinuations due to adverse events22, 23.
The results from this multicentre trial demonstrate
that levetiracetam has a favourable safety profile
when administered at optimised doses ranging from
1000 to 3000 mg day−1. In addition, levetiracetam
reduced seizure frequency in both partial and gener-
alised seizures. A high percentage of patients became
seizure-free for a clinically relevant period of more
than 6 months. Randomised controlled trials of lev-
etiracetam efficacy in generalised-onset seizures are
indicated.
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